HemoGenyx Pharmaceuticals (LON: HEMO) announced the approval of a crucial patent application by the United States Patent and Trademark Office, safeguarding its innovative CDX antibody technology.
The granted patent, titled ‘Method of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodies’, marks a significant milestone in the company’s intellectual property portfolio.
Vladislav Sandler, the Chief Executive Officer, commented, “The approval of this patent is a major enhancement to our intellectual property rights surrounding CDX, which continues to be a pivotal product candidate for our future endeavours. This achievement further establishes our firm’s leadership in the field of conditioning for bone marrow transplants.”
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
